Business
Collegium Provides 2022 Financial Guidance
– Total Product Revenues Expected in the Range of $450.0 million to $465.0 million – – Adjusted Operating Expenses Expected in the Range of $130.0 million to
About this update from Collegium Pharmaceutical, Inc.
[{"type":"text","content":"– Total Product Revenues Expected in the Range of $450.0 million to $465.0 million – – Adjusted Operating Expenses Expected in the Range of $130.0 million to $140.0 million – – Adjusted EBITDA Expected in the Range of $235.0 million to $250.0 million – STOUGHTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced updated financial guidance for the full year 2022 to include the expected impact of the BioDelivery Sciences International Inc. (“BDSI”) acquisition. As previously announced, the Company completed the acquisition of BDSI on March 22, 2022. “2022 is a pivotal year, as we take actions to advance our mission of building a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “Near-term, we are laser-focused on seamless integration of BDSI, maximizing the potential of the portfolio, renegotiation of Xtampza ER contracts to ensure","length":1905,"tagName":"div"}]